UK markets open in 3 hours 6 minutes

KALA BIO, Inc. (0JQ2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.51-1.16 (-17.39%)
At close: 04:40PM BST
Full screen
Previous close6.67
BidN/A x N/A
AskN/A x N/A
Day's range0.00 - 0.00
52-week range
Avg. volume320
Market capN/A
Beta (5Y monthly)-1.97
PE ratio (TTM)N/A
Earnings date02 Aug 2024 - 06 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    KALA BIO to Present at Jefferies Global Healthcare Conference

    ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be av

  • Insider Monkey

    Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)

    European stocks started the day on May 21 with a slightly weaker note, marking a retreat from their recent impressive performance, with attention now shifting towards the upcoming earnings report from NVIDIA. The Stoxx 600 index dipped by 0.2%, showing a predominantly negative trend across most sectors, while futures for US equities remained relatively unchanged. […]

  • GlobeNewswire

    KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

    -- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- -- Cash resources of $48.5 million as of March 31, 2024 together with anticipated funding remaining from CIRM award expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- KALA BIO